Adipose tissue derived mesenchymal stem cells for musculoskeletal repair in veterinary medicine by Arnhold, Stefan & Wenisch, Sabine
Am J Stem Cells 2015;4(1):1-12
www.AJSC.us /ISSN:2160-4150/AJSC0005897
Review Article 
Adipose tissue derived mesenchymal stem cells for 
musculoskeletal repair in veterinary medicine
Stefan Arnhold1, Sabine Wenisch2 
1Department of Veterinary Anatomy-, Histology and -Embryology, University of Giessen, Giessen, Germany; 2De-
partment of Veterinary Clinical Sciences, Small Animal Clinic c/o Institute of Veterinary Anatomy-, Histology and 
-Embryology, University of Giessen, Frankfurter Str. 98. 35394, Giessen, Germany
Received January 14, 2015; Accepted January 28, 2015; Epub March 15, 2015; Published March 31, 2015
Abstract: Adipose tissue derived stem cells (ASCs) are mesenchymal stem cells which can be obtained from differ-
ent adipose tissue sources within the body. It is an abundant cell pool, which is easy accessible and the cells can 
be obtained in large numbers, cultivated and expanded in vitro  and prepared for tissue engineering approaches, 
especially for skeletal tissue repair. In the recent years this cell population has attracted a great amount of attention 
among researchers in human as well as in veterinary medicine. In the meantime ASCs have been well characterized 
and their use in regenerative medicine is very well established. This review focuses on the characterization of ASCs 
for their use for tissue engineering approaches especially in veterinary medicine and also highlights a selection of 
clinical trials on the basis of ASCs as the relevant cell source.
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Introduction 
Mesenchymal stem cells are one type of adult 
stem cells which were originally identified as 
multi-potent cells isolated from the bone mar-
row [1, 2]. Later on Caplan and co-workers used 
the term mesenchymal stem cells (MSCs) [3]. 
They described them as clonal, plastic adher-
ent, non-hematopoetic cells, which are the 
source for mesodermal cell lineages such as 
osteoblasts, chondroblasts and adipocytes [1]. 
Additionally, mesenchymal stem cells also have 
an endodermal and a neuroectodermal differ-
entiation potential, which has so far only been 
shown in vitro [4-6]. After their discovery MSCs 
have been isolated from nearly all tissues of 
the body, for example bone marrow and adi-
pose tissue [7], umbilical cord blood [8], syno-
via [9], periost [10], skeletal muscle [11], lung 
[12], teeth [13], skin [14] blood [15] and bone 
[16]. 
Similar to other stem cells MSCs are present in 
the different tissues throughout life. However, 
their number is correlated inversely with the 
health status as well as with age and tissue ori-
gin [17]. MSCs play a very important role in all 
mature tissues, thus it is assumed that they 
form a kind of pool of cells for tissue repair, 
which can be mobilized rather quickly during 
injury and disease [18].
These cells are able to synthesize a broad vari-
ety of growth factors and cytokines, which may 
influence cells in their proximate vicinity [19]. 
Thus, bioactive factors secreted by MSCs may 
have an autocrine or paracrine effect on the 
local environment [20].
Adipose tissue derived stem cells
Adult adipose tissue is the source of fibroblast-
like cells capable of multipotential differentia-
tion in a number of species [21-24]. These cells 
were first identified as MSCs in human adipose 
tissue in 2001 [5, 7]. During the following years 
the establishment of this tissue as a cell source 
for MSCs suitable for tissue engineering and 
regenerative medicine was continuously pro-
moted. They could be isolated from lipoaspirate 
and after isolation they exhibited an osteogen-
ic, adipogenic, myogenic and chondrogenic dif-
ferentiation potential in vitro. As a variety of 
names were used to describe the plastic adher-
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ent cell population, in the year 2004 the “Fat 
Applied Technology Society” reached a consen-
sus to adopt the term adipose derived stem 
cells ASC [25]. There are several types of adi-
pose tissue as cell source for ASCs e.g. subcu-
taneous or abdominal fat tissue, with subcuta-
neous as the clinically most relevant source. 
Because white adipose tissue is the most 
abundant adipose tissue in the organism, ASCs 
are preferentially isolated from this tissue and 
they can be isolated without any major clinical 
risk. 
The initial method to isolate cells from the adi-
pose tissue was developed by Rodbell in the 
1960s [26] using rat fat pads. According to this 
protocol the tissue was minced and afterwards 
it undergoes enzymatic digestions with collage-
nase type II. Later on after centrifugation, the 
resulting cell pellet was called the stroma vas-
cular fraction (SVF). ASCs are obtained by plas-
tic adherence from the whole SVF, which also 
includes endothelial cells, pericytes, smooth 
muscle cells and blood cells [27]. Subsequently, 
this procedure has been modified for the isola-
tion of human adipose tissue specimens [7]. 
Isolation and culture of ASCs
Similar to the isolation of ASCs from human tis-
sue the isolation and characterization of ASCs 
from other species has been carried out just a 
few years later. Most of the species used 
served as translational models for human dis-
eases. Thus, it has been shown, that ASCs can 
be isolated from the adipose tissue of the 
mouse [28], rat [29], rabbit [30] and pig [31]. 
The isolation of ASCs for the actual application 
in veterinary regenerative medicine has been 
carried out in the horse [32] and in the dog 
[33]. The ASCs isolation method was based on 
the technique originally reported for human 
Figure 1. Isolation and preparation of equine ASCs in the cell culture lab. ASCs are isolated and prepared according 
the following procedure: A. Surgical resection of adipose tissue from the region of the horse’s tail. B. Adipose tissue 
dissolved in PBS in a Falcon tube. C. Mechanical disintegration of fat in the cell culture dish. D. Enzymatic digestion 
using collagenase I. E. After centrifugation the floating fat tissue is separated from the stromal vascular fraction at 
the bottom of the tube. F. After resuspension of the pellet in buffer (PBS) the suspension is filtered through a 70 
µm nylon cell strainer and centrifuged again. G. The resulting pellet after the second centrifugation step. H. After 
resuspension in the standard medium the cells are plated in cell culture flasks or petri dishes.
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ASC isolation [7, 34, 35]. Independent of the 
species the adipose tissue is collected either 
by needle biopsy or by liposuction aspiration.
While in the horse for the isolation of ASCs 
almost exclusively subcutaneous tissue is used 
which is preferentially collected from the region 
above the dorsal gluteal muscles [32] in ca- 
nines adipose tissue is additionally collected 
from the abdominal cavity as well as from ingui-
nal fat depots [33]. It could however been 
shown that there are individual factors as well 
as location dependent influences on the cell 
yield in the SVF [36].
After collection, the adipose tissue is washed in 
an equal volume of phosphate buffered saline 
(PBS) supplemented with 1% Penicillin/Stre- 
ptomycin. For transport reasons it can also be 
stored in PBS for a limited time. For cell isola-
tion the adipose tissue is minced and then 
undergoes enzymatic digestions using collage-
nase type I dissolved in BSA. The adipose tis-
sue within the enzymatic solution is placed in a 
water-bath at 37°C for 10 minutes and after-
wards in an incubator for about 30 minutes. 
The digested fat tissue is centrifuged for 5 min-
utes at 260 g. Afterwards the pellet is squashed 
through a 70 µm nylon cell strainer filter mesh 
and then pipetted into a 50 ml Falcon tube. The 
cells are washed in PBS at 300 g for 5 minutes 
and resuspended in 1 ml DMEM and 10% FCS. 
Finally, the cells are transferred to a culture 
dish at a density of 250.000 cells per cm2 
(Figure 1). After 24 h the cultures are washed 
with PBS to remove the nonadherent cells. 
During the expansion period, the medium is 
replaced three times per week. When the cells 
reach 80% of confluence, they are detached 
from the culture dish using accutase (PAA, 
Germany), then are washed with DMEM, count-
ed and plated again. For cryopreservation after 
passage 1, the cells are detached and sus-
pended in cryopreservation medium containing 
30% FCS and 10% dimethylsulfoxide [37, 38]. 
They are not negatively affected by the cryo-
preservation procedure so that long term stor-
age is guaranteed (Figure 2) [38-41].
Figure 2. Morphologic characterization of eqine ASCs. Morphological characterization is carried out in passage 3 
before and after cryopreservation. (A) Phase contrast micrograph of ASCs before cryopreservation. (B) Higher mag-
nification of (A). (C) Phase contrast micrograph of ASCs after cryopreservation and thawing, note the cell morpholo-
gies are not altered compared to (A). (D) Higher magnification of (C) no significant alteration of cell shape can be 
detected compared to non-cryopreserved cells. Scale bar in (A and C) = 50 µm, in (B and D) = 20 µm. 
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Characterization of ASCs
Similar to ASCs derived from human tissue, 
ASCs isolated from species relevant in veteri-
nary medicine are characterized by their plastic 
adherence and by stem cell specific marker 
expression. These are first of all the  stem cell 
specific markers associated with pluripotency 
such as Oct-4, Nanog and SOX2 in canine ASCs 
[33, 38] and also Oct4 and Nanog in equine 
ASCs [42], for review see [43]. According to the 
minimal standards set up by the international 
society for cellular therapy (ISCT) to character-
ize mesenchymal stem cells by the expression 
of certain cell surface markers, equine adipose 
derived stem cells have been shown to be addi-
tionally immunopositive for CD29, CD90, 
CD105 and CD73 and negative for the hemato-
poietic markers CD45, CD34, CD14, CD11b, 
CD79 alpha or CD19 as detected by immuno-
histochemistry but also quantified by flow 
cytometry [42], for review see [43]. Immuno- 
Figure 3. Differentiation lineages of ASCs. Schematic drawing of the most important mesenchymal differentiation 
lineages of adipose tissue derived stem cells. The most common and most important differentiation lineages are 
the osteogenic, chondrogenic and the adipogenic lineage. Additionally, in some reports also the tenogenic differen-
tiation potential is mentioned.
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phenotyping in canine ASCs using the surface 
markers as defined by the ISCT the majority of 
cells reveals the expression of CD44, CD29 
and CD90 [40], [38] while other markers, 
including CD14, CD34, CD44 and CD117 were 
consistently absent [40]. It has to be empha-
sized however, that according to the antibodies 
used expression rates may be either higher or 
lower or even absent at all.
Pluripotency of equine and canine ASCs is prov-
en by their differentiation capacity into multiple 
lineages under culturing with specific condi-
tions from which also their use for some of the 
clinical applications may be deduced (Figure 
3). For ASCs of both species (canine and 
equine) the adipogenic, osteogenic and chon-
drogenic differentiation can be shown using 
specific histological staining procedures (Figure 
4) [32, 33, 38, 42] and additionally by investi-
gating the expression of the adipogenic, osteo-
genic and chondrogenic marker genes amongst 
others RUNx2, Aggrecan and PPARγ2 [33, 38, 
40, 42, 44, 45]. In order to evaluate the poten-
cy of equine ASCs for an application in tendon 
regeneration additionally the tenogenic differ-
entiation of ASCs can be demonstrated using 
the combination of growth and differentiation 
factors as well as tensile strain and by carrying 
out a histological and PCR analysis for the teno-
genic marker genes COMP and Scleraxis [46]. 
Behavior of ASCs under special culture condi-
tions
In order to cultivate ASCs under conditions with 
the aim to improve their therapeutic potential 
there are several attempts to cultivate, expand 
and differentiate ASCs under special culture 
conditions. 
In many tissues and organs the oxygen tension 
is well below 21% with a mean tissue level of 
3% O2 [47]. Thus, the physiologic environment 
where MSCs reside is rather hypoxic and this is 
in contrast to culture conditions usually applied 
in in vitro cell and tissue culture. As the oxygen 
tension has an important role in the outcome of 
in vitro differentiation, there are several reports 
elucidating the culture of cells under various 
oxygen tensions. For equine ASCs some contra-
dictory results were published in the literature. 
On one hand it could be shown that while the 
proliferation rate of hypoxic ASCs was lower 
than in normoxic cells, because of a significant-
ly higher presence of dead cells, the immuno-
phenotype of both BMSCs and ASCs was main-
tained under both oxygen conditions. So it can 
be deduced that hypoxia attenuates the prolif-
erative capacity of equine MSCs but keeps 
them in a more undifferentiated state as em- 
bryonic markers are upregulated [48]. Besides 
an inhibited cell proliferation under hypoxia 
there are also hints for an altered differentia-
Figure 4. Histological staining procedures for demonstrating ASCs differentiation. Differentiation of canine ASCs 
into the three classical differentiation lineages after cultivation of cells in the appropriate differentiation media can 
be demonstrated using the characteristic staining procedures (A) red oil O for the adipogenic differentiation, (B) van 
Kossa for the osteogenic differentiation and (C) Alcian blue for the chondrogenic differentiation. Scale bar in (A) = 
12 µm, in (B) = 20 µm and in (C) = 25 µm.
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tion potential in equine ASCs. While the adipo-
genic and chondrogenic differentiation was 
improved under hypoxia, the osteogenic and 
tenogenic differentiation was more effective in 
21% O2 [45, 46]. These findings are in line with 
observations in canine MSCs in which an inhibi-
tory effect of hypoxia on both cell proliferation 
and differentiation could be observed [49]. For 
all these effects two aspects have to be taken 
into account: first of all the culture conditions in 
various studies such as passage number, me- 
dia, serum batch etc. may be different and sec-
ondly also interindividual differences in stem 
cell behavior have to be considered. 
It is also worthwhile considering the effects of 
the extracorporal shock wave (ESWT) on ASCs 
as in equine veterinary medicine ESWT is used 
to optimize healing conditions of bone, tendon 
as well as of cartilage. Moreover, a shock wave 
therapy is very often combined with a stem cell 
injection. One major effect of ESWT treatment 
of ASCs is the increase in the proliferation rate 
with a slightly improved differentiation poten-
tial. Especially the increased proliferation rate 
might give a hint for a possible endogenous 
stem cell activation within the treated tissue 
after ESWT application [50]. A similar approach 
was carried out by looking at the effect of a 
magnetic field on ASC behavior. This was actu-
ally done as devices that generate a static mag-
netic field are used in veterinary orthopedics 
especially for pain treatment termed magneto-
therapy. Based on this fact and the observation 
that magnetic fields activate microvesicles in 
stem cells, canine and equine ASCs have been 
exposed to a magnetic field produced by neo-
dymium magnets. Interestingly there were dif-
ferences between canine and equine ASCs 
under these conditions. While equine ASCs 
maintained a high proliferation rate and showed 
an increase of secretory microvesicles, canine 
ASCs reacted with a decreased proliferative 
activity and revealed a poor secretory activity 
[51].
Comparison of bone marrow and adipose tis-
sue derived stem cells
For regenerative therapies in veterinary medi-
cine the use of mesenchymal stem cells is 
increasingly discussed and actually applied. 
Consequently, there is the need for a compar-
ing the potency of bone marrow derived and 
adipose tissue derived stem cells as adipose 
derived stem cells are much easier to harvest. 
Such direct comparisons in regard of cell prolif-
eration, stem cell marker expression and lin-
eage specific differentiation potential have 
been carried out for equine as well as for canine 
mesenchymal stem cells of both tissues of ori-
gin. For equine MSCs it has been shown that 
the proliferation rate of ASCs is slightly lower 
than that of BMSCs, while stem marker expres-
sion is similar in both cell populations. In regard 
of the differentiation potential for all major dif-
ferentiation lineages there is no marked differ-
ence between both cell types [44]. However, 
high interindividual differences were observed 
in the proliferation capacity of both cell types, 
particularly in higher passages. For canine 
MSCs the situation is slightly different. While 
cells of both groups display a remarkable 
resemblance in morphology and expression of 
MSC-specific markers, they showed consider-
able differences in the proliferation rate and 
differentiation into the chondrogenic and osteo-
genic direction. Population doubling occurred 
significantly faster in ASCs compared to BMSCs 
[49]. However, the differentiation into the chon-
drogenic and osteogenic lineage was much 
weaker compared to BMSCs [38], while the 
adipogenic differentiation potential has been 
shown to be similar in both cell populations 
[52].
Therapeutic application of ASCs in equine 
veterinary medicine
Since mesenchymal stem cells have the poten-
cy to differentiate into cell types of the muscu-
loskeletal tissue, they are promising candidates 
for tissue engineering and regenerative medi-
cine in the equine patient. Cartilage lesions and 
cartilage degeneration, bone fractures and 
especially tendon lesions are extremely com-
mon in equine athletes. The lesions are known 
for their long recovery times and long non-pro-
ductive periods have to be taken into account 
[53]. The application of MSCs in tissue engi-
neering raise hopes for a faster healing and 
moreover, for complete regeneration after mus-
culoskeletal injuries [54]. There have been sev-
eral reports about the use of MSCs from differ-
ent sources for regenerative therapies in 
horses and so far the clinical outcome after 
using these alternative sources seems to be 
comparable with BMSCs. However, although 
ASCs have a similar differentiation potential as 
their bone marrow counterparts and their isola-
ASCs in veterinary medicine
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tion bears some significant advantages like 
their easy recovery, in veterinary medicine their 
disadvantages such as higher donor site mor-
bidity [55] is very often pronounced. In con-
trast, in human medicine a number of clinical 
approaches using ASC can be found through 
searches and on clinical trial web sites and 
thus, ASCs have prominent implications in tis-
sue regeneration due to their high cell yield in 
adipose tissue, the ability to differentiate into 
multiple lineages and the secretion of various 
cytokines and their immunomodulatory effects 
[56, 57]. Therefore, it is also worthwhile looking 
at regenerative approaches exclusively using 
ASCs in veterinary medicine. The application of 
ASCs has mainly been carried out in equine 
tendon regeneration [58]. A cell fraction called 
“adipose-derived mononuclear cells”, which 
contains in addition to ASCs also fibroblasts 
and other nucleated cells induced improved 
fiber linearity, uniformity and crimp pattern and 
a recovery of the tendon architecture after 
implantation in an experimentally induced ten-
don lesion using collagenase [59]. In a further 
clinical approach 16 horses were treated with 
allogenic ASCs grown in the presence of autolo-
gous platelet lysate. After the recovery period 
14 horses returned into working and remained 
active over the two year follow up period [60]. 
Similar results could also be shown in the 
course of an experimentally induced tendinitis 
using a collagenase gel, which was directly 
injected into the superficial digital flexor tendon 
of eight equines. Ultrasound assessment over 
16 weeks and histologic investigation revealed 
that the injection of ASCs suspended in platelet 
concentrate (PC) prevented the progression of 
the lesion and resulted in a greater organiza-
tion and decreased inflammation [61]. Fur- 
thermore, neovascularization was assessed in 
a standardized surgical model in superficial 
flexor digital tendons of nine horses 22 weeks 
after stem cell treatment [62]. The safety and 
efficacy of a therapy based on the use of alloge-
neic adipose tissue-derived mesenchymal 
stem cells (ASCs) in combination with platelet 
rich plasma (PRP) were evaluated in 19 horses 
affected by acute or subacute overstrain super-
ficial digital flexor tendonitis (SDFT). It could be 
shown that the application of allogeneic ASCs 
neither raised clinical sign of acute or chronic 
adverse tissue reactions, nor the formation of 
abnormal tissue in the long-term. Therefore, 
the combination of allogeneic ASCs and PRP 
can be considered as a safe and effective strat-
egy for the treatment of SDF tendonitis in the 
horse [63]. 
Besides the use of ASCs in tendon regenera-
tion there is also a report about the long-term 
beneficial influence of ASCs in horses suffering 
from bone spavin in comparison to routine ste-
roid injections [64]. So far there are no reports 
about an application of equine ASCs in carti-
lage regeneration.
Therapeutic application of ASCs in small ani-
mal veterinary medicine
The therapeutic application of ASCs in small 
animals is mainly restricted to canines and the 
clinical use in dogs seems to be rather versatile 
due to the differentiation potential of the cells 
as well as to the secretion of immunomodula-
tory factors. Based on the use of the dog as a 
model for human medicine, there are a number 
of studies dealing with regenerative processes, 
which may have additionally a significant 
impact also for veterinary medicine. While pub-
lications about the use of ASCs for the treat-
ment of central or peripheral nervous system 
lesions [65, 66] and for the treatment of cardio-
myopathies [67] are of barely scientific interest 
for human medicine, descriptions about the 
use of ASCs in orthopedic diseases have a 
much stronger association with applications in 
veterinary practice. The majority of studies 
focus on the use of ASCs in dogs with chronic 
osteoarthritis (OA). Thus, dogs suffering from 
OA of the hip or humeroradial joints treated 
with autologous ASCs within the whole SVF, had 
significantly improved scores for lameness, 
pain and range motion compared to control ani-
mals [68, 69]. In these cases the ASCs were 
not isolated from the SVF, so that a heteroge-
nous mixture of cells was injected into the 
lesioned sites. A similar approach was carried 
out in dogs with OA in humeroradial joints using 
isolated and well characterized ASCs having a 
significant potential for the treatment of lame-
ness [70]. In a force platform analysis of dogs 
treated with ASCs by direct injection into the 
hip joint by analyzing the vertical force and the 
vertical impulse revealed an objectively im- 
proved limb function after exclusive ASC treat-
ment [71]. However, it is questionable whether 
the observed beneficial effects exerted by 
ASCs are based on the secreted cytokines or 
on their differentiation capacity and thus on a 
ASCs in veterinary medicine
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direct impact on the regenerating cartilage. 
This question can only be elucidated if labelled 
stem cells for injection are used. However, 
these kind of experiments have only been car-
ried out using BMSCs in ovine and caprine OA 
animal models [72] in the course of histologic 
analysis carried out after euthanasia. 
The second major field of application for ASCs 
in small animal veterinary medicine is bone 
defects, which may occur in fractures associ-
ated with a massive loss of bone mass after 
trauma as well as after surgical resection of 
bone tumors or bone cysts. In case when spon-
taneous bone healing is hampered, usually 
autologous bone grafts or spongiosa are used 
to fill large bony defects. Alternatively to actual 
bone grafts isolated and expanded MSCs from 
bone marrow or adipose tissue in combination 
with scaffold materials can be used in order to 
achieve an osteogenic differentiation as well as 
an osteoinductive effect [73]. Interestingly, 
most approaches using BMSCs to treat bone 
defects in canines have been carried out in an 
experimental setting by creating an artificial 
critical size defects. However, as for the isola-
tion of autologous BMSCs an invasive surgical 
operation has to be applied, the isolation of 
ASCs represents a far less invasive procedure. 
Li et al. could demonstrate that the osteogenic 
and osteoinductive potential of BMSCs is much 
better than that of ASCs in an experimentally 
induced CSD in the ulnar bone [74]. In order to 
improve the osteoinductive characteristics, 
ASCs were pre-differentiated and additionally 
transduced with the gene coding for BMP-2, 
which is an osteogenic growth factor responsi-
ble for an improved osteogenic differentiation 
and therefore a better fracture healing. In a 
clinical study the effect of cells from the autolo-
gous SVF and that of allogenic ASCs was evalu-
ated in dogs with hip dysplasia after injection of 
cells into acupuncture points. After injection all 
animals showed an improved clinical condition 
and a reduced lameness. However, obviously 
positive results were more pronounced in the 
dogs treated with autologous SVF cells. Anyway, 
an important therapeutic alternative for the 
therapy of hip dysplasia is demonstrated [75].
Further studies on the use of ASCs in bone 
regeneration in dogs have been carried out on 
a more experimental level using the animals as 
models for bone defects in human medicine. 
Thus, new bone formation could be detected in 
mandibular bone [76] or in experimentally 
induced long bone defects using ASCs and the 
greater omentum as a scaffold material [77]. 
Furthermore, allogenic ASCs in combination 
with a coral scaffold have been shown to 
improve bone regeneration in bilateral cranial 
critical size defects using Beagle dogs [78]. 
Additionally, bone regeneration could also be 
demonstrated using ASCs incorporated into 
platelet rich plasma scaffolds transplanted into 
experimentally created tibia bone defects of six 
beagle dogs [79].
Legal aspects for the use of stem cells in 
veterinary medicine
Within the European Union the use of stem 
cells in human medicine is regulated by the 
European Medicines Agency, which follows 
research into the use of stem cells in medicines 
and is responsible for marketing-authorization 
applications for medicines containing stem 
cells. However, regardless the fact that medical 
products for the veterinary field are also regu-
lated and registered by the European Medicines 
Agency, for the use and application of stem 
cells of different sources including ASCs in vet-
erinary regenerative medicine there are cur-
rently no regulations applicable. This situation 
is similar in the United States, where the 
American Veterinary Medical Association moni-
tors legal and regulatory issues for the veteri-
nary practice. The use of medicinal products 
however is regulated by the US Food and Drug 
administration (FDA) [80], which is also respon-
sible for the regulations on the use of stem 
cells in humans. According to the situation in 
the EU, in the US regulations regarding the use 
of stem cells in veterinary medicine have not 
been installed yet, although in the meantime 
there is a widespread commercialization for 
cell based regenerative therapies [81], espe-
cially promoting the use of ASCs.
Conclusions
Out of adult mesenchymal stem cells ASCs 
have gained a high significance in experimental 
and clinical veterinary medicine. They can be 
characterized by their easy access, their good 
proliferative and differentiation properties. 
Furthermore, they secrete a variety of cytokines 
and growth factors and are outstanding 
because of their immunomodulatory effects. 
Because of the latter characteristic there is an 
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increase in studies promoting the use of allo-
genic cells for therapeutic usage. The number 
of clinical studies using ASCs for therapeutic 
applications in horses as well as in dogs is con-
tinuously rising, although they are in high com-
petition with studies using BMSCs or even the 
unpurified SVF. Nevertheless, the preparation 
and clinical use of ASCs in veterinary practice is 
increasingly commercialized. Further experi-
mental studies, also investigating the clinical 
effect of pre-differentiated cells or the possibil-
ity of a genetic modification of ASCs to promote 
the differentiation properties and to improve 
the clinical outcome have to be carried out in 
future. This should be done with regard to safe-
ty issues in order to guarantee the beneficial 
effects of this promising cell source also of allo-
genic origin for tissue engineering in veterinary 
medicine.
Acknowledgements
The authors wish to thank Manuela Heimann 
for technical assistance and for critically read-
ing the manuscript.
Disclosure of conflict of interest
The authors declare that there is no conflict of 
interests regarding the publication of this 
article.
Address correspondence to: Stefan Arnhold, Insti- 
tute of Veterinary-Anatomy, -Histology and -Embr- 
yology, Justus-Liebig University of Giessen, Giessen, 
Germany. Tel: +49-0641-9938100; Fax: +49-0641-
9938109; E-mail: Stefan.arnhold@vetmed.uni-gies-
sen.de
References 
[1] Friedenstein A. Precursor cells of mechano-
cytes. Int Rev Cytol 1976; 47: 327-359.
[2] Pittenger M, Mackay A, Beck S, Jaiswal R, 
Douglas R, Mosca J, Moorman M, Simonetti D, 
Craig S, Marshak D. Multilineage potential of 
adult human mesenchymal stem cells. Sci-
ence 1999; 5411: 143-147.
[3] Caplan A. Mesenchymal stem cells. J Orthop 
Res 1991; 5: 641-650.
[4] Takashima Y, Era T, Nakao K, Kondo S, Kasuga 
M, Smith A, Nishikawa SI. Neuroepithelial cells 
supply an initial transient wave of MSC differ-
entiation. Cell 2007; 7: 1377-1388.
[5] Wenisch S, Trinkaus K, Hild A, Hose D, Heiss C, 
Alt V, Klisch C, Meissl H, Schnettler R. Immuno-
chemical, ultrastructural and electrophysiolog-
ical investigations of bone-derived stem cells 
in the course of neuronal differentiation. Bone 
2006; 6: 911-921.
[6] Arnhold S, Klein H, Klinz FJ, Absenger Y, 
Schmidt A, Schinköthe T, Brixius K, Kozlowski 
J, Desai B, Bloch W, Addicks K. Human bone 
marrow stroma cells display certain neural 
characteristics and integrate in the subven-
tricular compartment after injection into the li-
quor system. Eur J Cell Biol 2006; 6: 551-565.
[7] Zuk P, Zhu M, Mizuno H, Huang J, Futrell J, Katz 
A, Benhaim P, Lorenz H, Hedrick M. Multilin-
eage cells from human adipose tissue: impli-
cations for cell-based therapies. Tissue Eng 
2001; 2: 211-228.
[8] Erices A, Conget P, Minguell J. Mesenchymal 
progenitor cells in human umbilical cord blood. 
Br J Haematol 2000; 1: 235-242.
[9] De Bari C, Dell’Accio F, Tylzanowski P, Luyten 
FP. Multipotent mesenchymal stem cells from 
adult human synovial membrane. Arthritis 
Rheum 2001; 8: 1928-1942.
[10] Fukumoto T, Sperling J, Sanyal A, Fitzsimmons 
J, Reinholz G, Conover C, O’Driscoll S. Com-
bined effects of insulin-like growth factor-1 and 
transforming growth factor-beta1 on periosteal 
mesenchymal cells during chondrogenesis in 
vitro. Osteoarthr Cartil 2003; 1: 55-64.
[11] Jankowski R, Deasy B, Huard J. Muscle-derived 
stem cells. Gene Ther 2002; 10: 642-647.
[12] Noort WA, Kruisselbrink AB, in’t Anker PS, Kru-
ger M, van Bezooijen RL, de Paus RA, Heem-
skerk MH, Löwik CW, Falkenburg JH, Willemze 
R, Fibbe WE. Mesenchymal stem cells promote 
engraftment of human umbilical cord blood-
derived CD34(+) cells in NOD/SCID mice. Exp 
Hematol 2002; 8: 870-878.
[13] Miura M, Gronthos S, Zhao M, Lu B, Fisher L, 
Robey P, Shi S. SHED: stem cells from human 
exfoliated deciduous teeth. Proc Natl Acad Sci 
U S A 2003; 10: 5807-5812.
[14] Young H, Steele T, Bray R, Hudson J, Floyd J, 
Hawkins K, Thomas K, Austin T, Edwards C, 
Cuzzourt J, Duenzl M, Lucas P, Black A. Human 
reserve pluripotent mesenchymal stem cells 
are present in the connective tissues of skele-
tal muscle and dermis derived from fetal, 
adult, and geriatric donors. Anat Rec 2001; 1: 
51-62.
[15] Zvaifler N, Marinova-Mutafchieva L, Adams G, 
Edwards C, Moss J, Burger J, Maini R. Mesen-
chymal precursor cells in the blood of normal 
individuals. Arthritis Res 2000; 6: 477-488.
[16] Wenisch S, Trinkaus K, Hild A, Hose D, Herde 
K, Heiss C, Kilian O, Alt V, Schnettler R. Human 
reaming debris: a source of multipotent stem 
cells. Bone 2005; 1: 74-83.
[17] Majors A, Boehm C, Nitto H, Midura R, Mus-
chler G. Characterization of human bone mar-
ASCs in veterinary medicine
10 Am J Stem Cells 2015;4(1):1-12
row stromal cells with respect to osteoblastic 
differentiation. J Orthop Res 1997; 4: 546-
557.
[18] Barry F, Murphy J. Mesenchymal stem cells: 
clinical applications and biological character-
ization. Int J Biochem Cell Biol 2004; 4: 568-
584.
[19] Haynesworth S, Baber M, Caplan A. Cytokine 
expression by human marrow-derived mesen-
chymal progenitor cells in vitro: effects of dexa-
methasone and IL-1 alpha. J Cell Physiol 1996; 
3: 585-592.
[20] Caplan A, Dennis J. Mesenchymal stem cells 
as trophic mediators. J Cell Biochem 2006; 5: 
1076-1084.
[21] Hollenberg C, Vost A. Regulation of DNA syn-
thesis in fat cells and stromal elements from 
rat adipose tissue. J Clin Invest 1969; 11: 
2485-2498.
[22] Dardick I, Poznanski W, Waheed I, Setterfield 
G. Ultrastructural observations on differentiat-
ing human preadipocytes cultured in vitro. Tis-
sue Cell 1976; 3: 561-571.
[23] Poznanski W, Waheed I, Van R. Human fat cell 
precursors. Morphologic and metabolic differ-
entiation in culture. Lab Invest 1973; 5: 570-
576.
[24] Dixon-Shanies D, Rudick J, Knittle J. Observa-
tons on the growth and metabolic functions of 
cultured cells derived from human adipose tis-
sue. Proc Soc Exp Biol Med 1975; 2: 541-545.
[25] Bunnell B, Flaat M, Gagliardi C, Patel B, Ripoll 
C. Adipose-derived stem cells: isolation, expan-
sion and differentiation. Methods 2008; 2: 
115-120.
[26] Rodbell M. Metabolism of isolated fat cells. II. 
The similar effects of phospholipase C (Clos-
tridium perfringens alpha toxin) and of insulin 
on glucose and amino acid metabolism. J Biol 
Chem 1966; 1: 130-139.
[27] Rodbell M, Jones A. Metabolism of isolated fat 
cells. 3. The similar inhibitory action of phos-
pholipase C (Clostridium perfringens alpha 
toxin) and of insulin on lipolysis stimulated by 
lipolytic hormones and theophylline. J Biol 
Chem 1966; 1: 140-142.
[28] Safford K, Hicok K, Safford S, Halvorsen YD, 
Wilkison W, Gimble J, Rice H. Neurogenic dif-
ferentiation of murine and human adipose-de-
rived stromal cells. Biochem Biophys Res Com-
mun 2002; 2: 371-379.
[29] Tholpady S, Katz A, Ogle R. Mesenchymal stem 
cells from rat visceral fat exhibit multipotential 
differentiation in vitro. Anat Rec A Discov Mol 
Cell Evol Biol 2003; 1: 398-402.
[30] Peptan I, Hong L, Mao J. Comparison of osteo-
genic potentials of visceral and subcutaneous 
adipose-derived cells of rabbits. Plast Reconstr 
Surg 2006; 5: 1462-1470.
[31] Qu CQ, Zhang GH, Zhang LJ, Yang GS. Osteo-
genic and adipogenic potential of porcine adi-
pose mesenchymal stem cells. In Vitro Cell Dev 
Biol Anim 2007; 2: 95-100.
[32] Vidal M, Kilroy G, Lopez M, Johnson J, Moore R, 
Gimble J. Characterization of equine adipose 
tissue-derived stromal cells: adipogenic and 
osteogenic capacity and comparison with 
bone marrow-derived mesenchymal stromal 
cells. Vet Surg 2007; 7: 613-622.
[33] Neupane M, Chang CC, Kiupel M, Yuzbasiyan-
Gurkan V. Isolation and characterization of ca-
nine adipose-derived mesenchymal stem cells. 
Tissue Eng Part A 2008; 6: 1007-1015.
[34] Lin TM, Tsai JL, Lin SD, Lai CS, Chang CC. Ac-
celerated growth and prolonged lifespan of 
adipose tissue-derived human mesenchymal 
stem cells in a medium using reduced calcium 
and antioxidants. Stem Cells Dev 2005; 1: 92-
102.
[35] Aust L, Devlin B, Foster S, Halvorsen, YDC, Hi-
cok K, Du Laney T, Sen A, Willingmyre G, Gim-
ble J. Yield of human adipose-derived adult 
stem cells from liposuction aspirates. Cytother-
apy 2004; 1: 7-14.
[36] Astor D, Hoelzler M, Harman R, Bastian R. Pa-
tient factors influencing the concentration of 
stromal vascular fraction (SVF) for adipose-de-
rived stromal cell (ASC) therapy in dogs. Can J 
Vet Res 2013; 3: 177-182.
[37] Raabe O, Reich C, Wenisch S, Hild A, Burg-
Roderfeld M, Siebert HC, Arnhold S. Hydro-
lyzed fish collagen induced chondrogenic dif-
ferentiation of equine adipose tissue-derived 
stromal cells. Histochem Cell Biol 2010; 6: 
545-554.
[38] Reich C, Raabe O, Wenisch S, Bridger P, Kram-
er M, Arnhold S. Isolation, culture and chon-
drogenic differentiation of canine adipose tis-
sue- and bone marrow-derived mesenchymal 
stem cells--a comparative study. Vet Res Com-
mun 2012; 2: 139-148.
[39] Gonda K, Shigeura T, Sato T, Matsumoto D, 
Suga H, Inoue K, Aoi N, Kato H, Sato K, Murase 
S, Koshima I, Yoshimura K. Preserved prolifer-
ative capacity and multipotency of human adi-
pose-derived stem cells after long-term cryo-
preservation. Plast Reconstr Surg 2008; 2: 
401-410.
[40] Vieira N, Brandalise V, Zucconi E, Secco M, 
Strauss B, Zatz M. Isolation, characterization, 
and differentiation potential of canine adi-
pose-derived stem cells. Cell Transplant 2010; 
3: 279-289.
[41] Mambelli L, Santos, Enrico J C, Frazão, Paulo J 
R, Chaparro M, Kerkis A, Zoppa, André LV, Ker-
kis I. Characterization of equine adipose tis-
sue-derived progenitor cells before and after 
cryopreservation. Tissue Eng Part C Methods 
2009; 1: 87-94.
ASCs in veterinary medicine
11 Am J Stem Cells 2015;4(1):1-12
[42] Raabe O, Shell K, Würtz A, Reich C, Wenisch S, 
Arnhold S. Further insights into the character-
ization of equine adipose tissue-derived mes-
enchymal stem cells. Vet Res Commun 2011; 
6: 355-365.
[43] Burk J, Badylak S, Kelly J, Brehm W. Equine cel-
lular therapy--from stall to bench to bedside? 
Cytometry A 2013; 1: 103-113.
[44] Ranera B, Lyahyai J, Romero A, Vázquez F, 
Remacha A, Bernal M, Zaragoza P, Rodellar C, 
Martín-Burriel I. Immunophenotype and gene 
expression profiles of cell surface markers of 
mesenchymal stem cells derived from equine 
bone marrow and adipose tissue. Vet Immunol 
Immunopathol 2011; 144: 147-154.
[45] Shell K, Raabe O, Freitag C, Ohrndorf A, Christ 
HJ, Wenisch S, Arnhold S. Comparison of 
Equine Adipose Tissue-Derived Stem Cell Be-
havior and Differentiation Potential Under the 
Influence of 3% and 21% Oxygen Tension. Jour-
nal of Equine Veterinary Science 2013; 2: 74-
82.
[46] Raabe O, Shell K, Fietz D, Freitag C, Ohrndorf 
A, Christ H, Wenisch S, Arnhold S. Tenogenic 
differentiation of equine adipose-tissue-de-
rived stem cells under the influence of tensile 
strain, growth differentiation factors and vari-
ous oxygen tensions. Cell Tissue Res 2013; 3: 
509-521.
[47] Csete M. Oxygen in the cultivation of stem 
cells. Ann N Y Acad Sci 2005; 1049: 1-8.
[48] Ranera B, Remacha A, Álvarez-Arguedas S, 
Romero A, Vázquez F, Zaragoza P, Martín-Burri-
el I, Rodellar C. Effect of hypoxia on equine 
mesenchymal stem cells derived from bone 
marrow and adipose tissue. BMC Vet Res 
2012; 8: 142.
[49] Chung DJ, Hayashi K, Toupadakis C, Wong A, 
Yellowley C. Osteogenic proliferation and differ-
entiation of canine bone marrow and adipose 
tissue derived mesenchymal stromal cells and 
the influence of hypoxia. Res Vet Sci 2012; 1: 
66-75.
[50] Raabe O, Shell K, Goessl A, Crispens C, Del-
hasse Y, Eva A, Scheiner-Bobis G, Wenisch S, 
Arnhold S. Effect of extracorporeal shock wave 
on proliferation and differentiation of equine 
adipose tissue-derived mesenchymal stem 
cells in vitro. Am J Stem Cells 2013; 1: 62-73.
[51] Marędziak M, Marycz K, Smieszek A, Lewan-
dowski D, Toker N. The influence of static mag-
netic fields on canine and equine mesenchy-
mal stem cells derived from adipose tissue. In 
Vitro Cell Dev Biol Anim 2014; 6: 562-571.
[52] Takemitsu H, Zhao D, Yamamoto I, Harada Y, 
Michishita M, Arai T. Comparison of bone mar-
row and adipose tissue-derived canine mesen-
chymal stem cells. BMC Vet Res 2012; 8: 150.
[53] Bailey C, Reid S, Hodgson D, Rose R. Impact of 
injuries and disease on a cohort of two- and 
three-year-old thoroughbreds in training. Vet 
Rec 1999; 17: 487-493.
[54] Koch T, Berg L, Betts D. Current and future re-
generative medicine-principles, concepts, and 
therapeutic use of stem cell therapy and tissue 
engineering in equine medicine. Can Vet J 
2009; 2: 155-165.
[55] Richardson L, Dudhia J, Clegg P, Smith R. Stem 
cells in veterinary medicine--attempts at re-
generating equine tendon after injury. Trends 
Biotechnol 2007; 9: 409-416.
[56] Nauta A, Fibbe W. Immunomodulatory proper-
ties of mesenchymal stromal cells. Blood 
2007; 10: 3499-3506.
[57] Tsuji W, Rubin J, Marra K. Adipose-derived 
stem cells: Implications in tissue regeneration. 
World J Stem Cells 2014; 3: 312-321.
[58] Reed S, Leahy E. Growth and Development 
Symposium: Stem cell therapy in equine ten-
don injury. J Anim Sci 2013; 1: 59-65.
[59] Nixon A, Dahlgren L, Haupt J, Yeager A, Ward D. 
Effect of adipose-derived nucleated cell frac-
tions on tendon repair in horses with collage-
nase-induced tendinitis. Am J Vet Res 2008; 7: 
928-937.
[60] Del Bue M, Riccò S, Ramoni R, Conti V, Gnudi 
G, Grolli S. Equine adipose-tissue derived mes-
enchymal stem cells and platelet concen-
trates: their association in vitro and in vivo. Vet 
Res Commun 2008; 32 Suppl 1: S51-5.
[61] Carvalho, Armando de Mattos, Badial P, Álva-
rez, Luis Emiliano Cisneros, Yamada, Ana Lucia 
Miluzzi, Borges A, Deffune E, Hussni C, Garcia 
Alves, Ana Liz. Equine tendonitis therapy using 
mesenchymal stem cells and platelet concen-
trates: a randomized controlled trial. Stem Cell 
Res Ther 2013; 4: 85.
[62] Conze P, van Schie, Hans T M, van Weeren R, 
Staszyk C, Conrad S, Skutella T, Hopster K, 
Rohn K, Stadler P, Geburek F. Effect of autolo-
gous adipose tissue-derived mesenchymal 
stem cells on neovascularization of artificial 
equine tendon lesions. Regen Med 2014; 6: 
743-757.
[63] Ricco S, Renzi S, Del Bue M, Conti V, Merli E, 
Ramoni R, Lucarelli E, Gnudi G, Ferrari M, Grol-
li S. Allogeneic adipose tissue-derived mesen-
chymal stem cells in combination with platelet 
rich plasma are safe and effective in the thera-
py of superficial digital flexor tendonitis in the 
horse. Int J Immunopathol Pharmacol 2013; 1 
Suppl: 61-68.
[64] Nicpoń J, Marycz K, Grzesiak J. Therapeutic ef-
fect of adipose-derived mesenchymal stem 
cell injection in horses suffering from bone 
spavin. Pol J Vet Sci 2013; 4: 753-754.
[65] Ryu H, Lim J, Byeon Y, Park J, Seo M, Lee Y, Kim 
W, Kang K, Kweon O. Functional recovery and 
neural differentiation after transplantation of 
allogenic adipose-derived stem cells in a ca-
ASCs in veterinary medicine
12 Am J Stem Cells 2015;4(1):1-12
nine model of acute spinal cord injury. J Vet Sci 
2009; 4: 273-284.
[66] Ghoreishian M, Rezaei M, Beni B, Javanmard 
S, Attar B, Zalzali H. Facial nerve repair with 
Gore-Tex tube and adipose-derived stem cells: 
an animal study in dogs. J Oral Maxillofac Surg 
2013; 3: 577-587.
[67] Pogue B, Estrada A, Sosa-Samper I, Maisen-
bacher H, Lamb K, Mincey B, Erger K, Conlon T. 
Stem-cell therapy for dilated cardiomyopathy: 
a pilot study evaluating retrograde coronary ve-
nous delivery. J Small Anim Pract 2013; 7: 
361-366.
[68] Black L, Gaynor J, Gahring D, Adams C, Aron D, 
Harman S, Gingerich D, Harman R. Effect of 
adipose-derived mesenchymal stem and re-
generative cells on lameness in dogs with 
chronic osteoarthritis of the coxofemoral 
joints: a randomized, double-blinded, multi-
center, controlled trial. Vet Ther 2007; 4: 272-
284.
[69] Black L, Gaynor J, Adams C, Dhupa S, Sams A, 
Taylor R, Harman S, Gingerich D, Harman R. Ef-
fect of intraarticular injection of autologous 
adipose-derived mesenchymal stem and re-
generative cells on clinical signs of chronic os-
teoarthritis of the elbow joint in dogs. Vet Ther 
2008; 3: 192-200.
[70] Guercio A, Di Marco P, Casella S, Cannella V, 
Russotto L, Purpari G, Di Bella S, Piccione G. 
Production of canine mesenchymal stem cells 
from adipose tissue and their application in 
dogs with chronic osteoarthritis of the humero-
radial joints. Cell Biol Int 2012; 2: 189-194.
[71] Vilar J, Batista M, Morales M, Santana A, Cu-
ervo B, Rubio M, Cugat R, Sopena J, Carrillo J. 
Assessment of the effect of intraarticular injec-
tion of autologous adipose-derived mesenchy-
mal stem cells in osteoarthritic dogs using a 
double blinded force platform analysis. BMC 
Vet Res 2014; 10: 143.
[72] Murphy J, Fink D, Hunziker E, Barry F. Stem cell 
therapy in a caprine model of osteoarthritis. 
Arthritis Rheum 2003; 12: 3464-3474.
[73] Harasen G. Stimulating bone growth in the 
small animal patient: Grafts and beyond! Can 
Vet J 2011; 2: 199-200.
[74] Li H, Dai K, Tang T, Zhang X, Yan M, Lou J. Bone 
regeneration by implantation of adipose-de-
rived stromal cells expressing BMP-2. Bio-
chem. Biophys Res Commun 2007; 4: 836-
842.
[75] Marx C, Silveira M, Selbach I, da Silva, Ariel Sil-
veira, Braga, Luisa Maria Gomes de Macedo, 
Camassola M, Nardi N. Acupoint injection of 
autologous stromal vascular fraction and allo-
geneic adipose-derived stem cells to treat hip 
dysplasia in dogs. Stem Cells Int 2014; 2014: 
391274.
[76] Haghighat A, Akhavan A, Hashemi-Beni B, Dei-
himi P, Yadegari A, Heidari F. Adipose derived 
stem cells for treatment of mandibular bone 
defects: An autologous study in dogs. Dent Res 
J (Isfahan) 2011; 8 Suppl 1: S51-7.
[77] Bigham-Sadegh A, Mirshokraei P, Karimi I, Ory-
an A, Aparviz A, Shafiei-Sarvestani Z. Effects of 
adipose tissue stem cell concurrent with great-
er omentum on experimental long-bone heal-
ing in dog. Connect Tissue Res 2012; 4: 334-
342.
[78] Liu G, Zhang Y, Liu B, Sun J, Li W, Cui L. Bone 
regeneration in a canine cranial model using 
allogeneic adipose derived stem cells and cor-
al scaffold. Biomaterials 2013; 11: 2655-
2664.
[79] Cruz, Ariadne Cristiane Cabral, Caon T, Menin 
A, Granato R, Boabaid F, Simões, Cláudia Ma-
ria Oliveira. Adipose-derived stem cells incor-
porated into platelet-rich plasma improved 
bone regeneration and maturation in vivo. 
Dent Traumatol 2014; 31: 42-8. 
[80] Nobert K. The regulation of veterinary regen-
erative medicine and the potential impact of 
such regulation on clinicians and firms com-
mercializing these treatments. Vet Clin North 
Am Equine Pract 2011; 2: 383-391.
[81] Volk S, Theoret C. Translating stem cell thera-
pies: the role of companion animals in regen-
erative medicine. Wound Repair Regen 2013; 
3: 382-394.
